Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography
Phase 3
Recruiting
- Conditions
- Cardiac Diseases
- Interventions
- Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Trust Bio-sonics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06815627
- Locations
- 🇨🇳
Keelung Chang Gung Memorial Hospital & Lovers Lake Branch, Keelung, Taiwan
🇨🇳China Medical University Hospital, Taichung, Taiwan
🇨🇳MacKay Memorial Hospital, Taipei, Taiwan
A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography
Phase 1
Completed
- Conditions
- Cardiac Disease
- Interventions
- Drug: NH002 (Perflutren Lipid Microspheres) Injectable SuspensionDiagnostic Test: Echocardiogram
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Trust Bio-sonics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04185246
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Taipei Mackay Memorial Hospital, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath